HER-2, notch, and breast cancer stem cells: Targeting an axis of evil

Hasan Korkaya; Max S. Wicha

doi:10.1158/1078-0432.CCR-08-3087

HER-2, notch, and breast cancer stem cells: Targeting an axis of evil

Hasan Korkaya, Max S. Wicha

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Abstract

Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

Original language	English (US)
Pages (from-to)	1845-1847
Number of pages	3
Journal	Clinical Cancer Research
Volume	15
Issue number	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-08-3087
State	Published - Mar 15 2009
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-08-3087

Cite this

@article{2db052dd8020464db6c107bbf52236ac,

title = "HER-2, notch, and breast cancer stem cells: Targeting an axis of evil",

abstract = "Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.",

author = "Hasan Korkaya and Wicha, {Max S.}",

year = "2009",

month = mar,

day = "15",

doi = "10.1158/1078-0432.CCR-08-3087",

language = "English (US)",

volume = "15",

pages = "1845--1847",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - HER-2, notch, and breast cancer stem cells

T2 - Targeting an axis of evil

AU - Korkaya, Hasan

AU - Wicha, Max S.

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

AB - Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse,suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

UR - http://www.scopus.com/inward/record.url?scp=63449116164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449116164&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-3087

DO - 10.1158/1078-0432.CCR-08-3087

M3 - Article

C2 - 19276254

AN - SCOPUS:63449116164

SN - 1078-0432

VL - 15

SP - 1845

EP - 1847

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -

HER-2, notch, and breast cancer stem cells: Targeting an axis of evil

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this